tumor infiltrating lymphocytes

Turnstone Bio Goes IPO to Fund Clinical Tests of New Kind of Cancer Cell Therapy

Turnstone Biologics isn’t the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.

By Frank Vinluan

BioPharma, Startups

Achilles Therapeutics raises $120M in Series B round for cancer cell therapy

The company is developing tumor-infiltrating lymphocyte therapies that target patient-specific neoantigens. It plans to use the money to fund Phase I/IIa studies in solid tumors.

By Alaric DeArment

Where Will AI Deployment Benefit Payers the Most?

We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.

By MedCity News

The Healthcare Payments Industry Faces a Perception Challenge

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum